481,679 Shares in Metsera Inc. (NASDAQ:MTSR) Bought by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA purchased a new position in shares of Metsera Inc. (NASDAQ:MTSR - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 481,679 shares of the company's stock, valued at approximately $13,111,000. Massachusetts Financial Services Co. MA owned 0.46% of Metsera as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of MTSR. New York State Common Retirement Fund purchased a new stake in shares of Metsera during the first quarter worth $131,000. Bank of New York Mellon Corp acquired a new position in shares of Metsera during the first quarter worth $884,000. Finally, Alphabet Inc. acquired a new position in shares of Metsera during the first quarter worth $135,059,000.

Analyst Ratings Changes

MTSR has been the subject of a number of analyst reports. Wells Fargo & Company initiated coverage on shares of Metsera in a research note on Friday, June 20th. They set an "overweight" rating and a $65.00 target price for the company. Guggenheim upped their price objective on shares of Metsera from $56.00 to $62.00 and gave the company a "buy" rating in a research note on Tuesday, June 10th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Metsera currently has an average rating of "Buy" and a consensus target price of $55.00.

Metsera Stock Performance

Shares of MTSR traded up $0.54 during mid-day trading on Wednesday, hitting $39.99. 839,704 shares of the company's stock were exchanged, compared to its average volume of 748,355. Metsera Inc. has a fifty-two week low of $12.30 and a fifty-two week high of $47.40. The company has a 50 day simple moving average of $31.34.

Metsera (NASDAQ:MTSR - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($1.03) earnings per share (EPS) for the quarter.

Metsera Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.